Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;10(2):123-125.
doi: 10.1016/S2213-2600(21)00450-1. Epub 2021 Nov 11.

Intravenous immunoglobulin therapy for COVID-19 ARDS

Erin M Wilfong  1 , Michael A Matthay  2
Affiliations

Intravenous immunoglobulin therapy for COVID-19 ARDS

Erin M Wilfong et al. Lancet Respir Med. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

EMW reports support from the National Institutes of Health (NIH); and reports research funding and consulting fees from Boehringer-Ingelheim, outside of the submitted work. MAM reports funding from the NIH, outside the submitted work; and consulting fees from Citrus Pharmaceuticals, outside the submitted work.

References

    1. Schurink B, Roos E, Radonic T, et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe. 2020;1:e290–e299. - PMC - PubMed
    1. The RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2020;384:693–704. - PMC - PubMed
    1. The WHOREAfC-TWG Association between administration of il-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326:499–518. - PMC - PubMed
    1. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021 doi: 10.1016/S2213-2600(21)00331-3. published online Sept 1. - DOI - PMC - PubMed
    1. Matthay MA, Luetkemeyer AF. IL-6 receptor antagonist therapy for patients hospitalized for COVID-19: who, when, and how? JAMA. 2021;326:483–485. - PubMed

Substances